Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (94)	7/11/2002 11:41:23 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 684

>> First of all, it wasn't already known that the trial would fail. My skepticism with regards to pleconaril is largely based on my opinion that it would have limited application medically. << I said Wyeth, not Aventis. And I wasn't talking about pleconaril or even 50406, but the next molecule, due in phase I this year. You popped into the thread to tell us that a company with $180M in the bank, a market cap of $28M, Wyeth as a freshly-renewed partner for HCV, and a RSV candidate scheduled for phase II this year was "dead meat". You further went on to tell us that all targets for RNA viruses had been completely studied. But then you pulled the really good one..... paraphrased..... "if big pharma can't succeed, why should a little biotech". I trained in pharma. Big, slow behemoths with lazy people. I can generalize too. Given your background, we could use your opinion AFTER you do some research. Thanks in advance.